ETCTN LAO-MD017 10010: A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer
Sponsor: |
NCI |
Enrolling: |
Female Patients Only |
IRB Number: |
AAAR4617 |
U.S. Govt. ID: |
NCT02921269 |
Contact: |
Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu |
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer. The purpose of this study is to test any good and bad effects of a combination of study drugs called atezolizumab and bevacizumab. The combination of atezolizumab and bevacizumab could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drugs will shrink the cancer by at least one quarter compared to its present size.
This study is closed
Investigator
Jason Wright, MD
Have you been diagnosed with cervical cancer? |
Yes |
No |